Last reviewed · How we verify

AZD9773 — Competitive Intelligence Brief

AZD9773 (AZD9773) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MyD88 inhibitor. Area: Immunology.

phase 2 MyD88 inhibitor MyD88 (Myeloid Differentiation Primary Response 88) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

AZD9773 (AZD9773) — AstraZeneca. AZD9773 is a selective inhibitor of myeloid differentiation primary response 88 (MyD88) that blocks innate immune signaling to reduce inflammatory responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD9773 TARGET AZD9773 AstraZeneca phase 2 MyD88 inhibitor MyD88 (Myeloid Differentiation Primary Response 88)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MyD88 inhibitor class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD9773 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9773. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: